Erin Colgan has more than twenty years of finance and accounting experience, with more than ten years making strategic financial and operational decisions for public and private, small- and large-cap life sciences firms.
In her current role at Sensei Biotherapeutics, Ms. Colgan leads the finance and operations team she built to transition to a quarterly reporting structure as a publicly held company following a successful IPO in February 2021. She also collaborates with Sensei leadership to manage investor and banking relations, while working closely with the Board on the Audit Committee and Compensation Committees.
Prior to Sensei, she served as vice president of FP&A and commercial planning at Intarcia Therapeutics, running the annual budgeting process as the company prepared to launch a Type II diabetes product. At Vertex Pharmaceuticals, Ms. Colgan held numerous finance and accounting leadership roles. She served as Controller in U.K. operations, supporting the launch of the company’s global CF franchise. There she led the operations team in creating new entities in Europe, Australia, and South America. She also collaborated with senior leadership to oversee all G&A expenses, commercial expenses, inventory cost planning, and global revenue planning and commercial forecasting.
Ms. Colgan began her career in public accounting at PwC where she worked in both audit and business development. She holds a B.A. in accounting from the University of Massachusetts, Amherst.